Avacta Group | AVA6000 positive Phase 1a Arm 2 update
Avacta has announced the successful completion of patient dosing in the first cohort of the two weekly dosing regimen in Arm 2 of the Phase 1a tolerability clinical study of AVA6000 with no adverse safety signals. Three patients have now been dosed in the second cohort. The company has also announced the initiation of a sub-study with SOFIE Biosciences (SOFIE) to better characterise the entire spread of cancer and related levels of FAP in selected patients with a view to identifying the target cancers most likely to respond to AVA6000 for when the Phase 1 study proceeds to test for efficacy in Phase 1b. Avacta remains on track to commence the dose expansion Phase 1b efficacy study and to present further data from the AVA6000 trial in 2H24.Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.